Tradestie Institutional Equity Comparison Engine

ABOS vs PYPD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PYPD Overall Edge

PYPD Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PolyPid Ltd. Ordinary Shares (PYPD) driven by superior Momentum & Technical, Options & Structure while ABOS counters with relative strength in Growth & Margin. Fundamentally, ABOS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PYPD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABOS sits in UNCLASSIFIED (41st %ile IV; Dealer Gamma Walls on Pro) against PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABOS N/M vs PYPD N/M Fwd P/E
Growth & Margin Winner ABOS
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner PYPD
1Y -87.6% vs +79.2% ยท 52W Pos 1% vs 80%
Options & Structure Winner PYPD
UNCLASSIFIED (41st %ile IV) vs BREAKOUT (12th %ile IV)
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.21
-0.97% 1D
Market Cap $15.5M
1M Return -87.92%
1Y Return -87.64%
Forward P/E N/M
Unified AI Score
49.5 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 68.0 Mom 55.0
PYPD NASDAQ
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
1M Return +31.86%
1Y Return +79.25%
Forward P/E N/M
Unified AI Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABOS -87.64% PYPD +79.25% Spread: +166.89 pp (PYPD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABOS TTM Op. Margin: 0.0% PYPD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABOS vs PYPD. Trailing 12-month operating profitability (ABOS 0.0% vs PYPD 0.0%) and valuation multiples (ABOS N/M vs PYPD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABOS (2) vs PYPD (3)
Institutional Metric ABOS PYPD Criterion Row Winner
Market Capitalization Scale $15.5M $132.2M Larger Scale PYPD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -162.7% -243.6% Higher ROE ABOS
52-Week Range Position Momentum 1% ($0โ€“$4) 80% ($4โ€“$7) Stronger Trend PYPD
Beta / 30D Volatility Risk Regime 2.63ฮฒ ยท 327% Vol 0.89ฮฒ ยท 59% Vol Lower Realized Risk PYPD
Unified Institutional Score Composite Signal 49.5 / 100 (HOLD) 31.1 / 100 (SELL) Higher Composite ABOS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABOS vs PYPD Buy Guide
ABOS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 41st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABOS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PYPD BREAKOUT
40d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live PYPD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABOS nor PYPD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.